Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies
| Autor: | B. Quadbeck, Anja Eckstein, Marco Plicht, Nils G. Morgenthaler, Joachim Esser, Klaus Mann, Herbert Hirche, Klaus P. Steuhl, Hildegard Lax |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Male
endocrine system medicine.medical_specialty Time Factors endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Graves' disease Anti-Inflammatory Agents Thyroid Gland Medizin Trab Iodide Peroxidase Thyroglobulin Fluocortolone Iodine Radioisotopes Graves' ophthalmopathy Endocrinology Thyroid peroxidase Internal medicine Humans Medicine Euthyroid Autoantibodies Retrospective Studies biology business.industry Autoantibody Receptors Thyrotropin Odds ratio Middle Aged medicine.disease Graves Disease Logistic Models biology.protein Female business Immunoglobulins Thyroid-Stimulating |
| Popis: | Summary objective Graves’ ophthalmopathy (GO) is clinically associated with autoimmune thyroid disease, and autoantibodies to thyroidal antigens, especially to the TSH-receptor (TRAb), might be involved in the disease process. While there is mounting evidence that TRAb are associated with GO at the onset of the disease, so far no studies have looked at the association between thyroidal autoantibodies and the clinical outcome of GO therapy. The aim of this retrospective study was to evaluate whether TSH binding inhibitory immunoglobulins (TBII) and thyroid stimulating antibodies (TSAb) are still associated with the clinical activity and severity of GO after the completion of anti-inflammatory therapy. In addition, we wanted to elucidate whether thyroid peroxidase (TPO) or thyroglobulin (TG) autoantibodies (TPOAb and TGAb) are in any way related to GO. design patients and measurements Clinical activity score (CAS) and the severity of GO (modified NOSPECS score) were assessed in 108 patients with GO after steroid therapy and, if indicated, orbital irradiation. Patients were grouped according to their clinical presentation and autoantibody levels (TBII, TSAb, TPOAb and TGAb) were measured. After therapy for hyperthyroidism, all patients were clinically euthyroid but showed clear heterogeneity for GO 4–12 months after the end of anti-inflammatory therapy. Fifty-two patients had inactive GO, 41 had moderately active and 15 still had very active (non-responsive) GO. Concerning severity, 27 patients had mild GO, 64 moderately severe and 17 severe GO. results TBII titres were still positive in 14 (93%) of 15 patients in the non-responsive group (CAS > 6) compared to 22 (42%) of 52 patients (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|